Scott N. Boyle - 13 Feb 2025 Form 4 Insider Report for C4 Therapeutics, Inc. (CCCC)

Reporting relationship: Chief Business Officer
Issuer ticker: CCCC
Reported as of: 13 Feb 2025
Net transaction value: -$16,733
SEC form: 4
Accepted by SEC: 18 Feb 2025, 16:55:16 UTC
Prior SEC filing: 12 Nov 2024
Next SEC filing: 18 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Shagha Russell, Attorney-in-Fact

Key filing fact

Scott N. Boyle filed Form 4 for C4 Therapeutics, Inc. (CCCC) on 18 Feb 2025.

Key facts

This page summarizes Scott N. Boyle's Form 4 filing for C4 Therapeutics, Inc. (CCCC).
6 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 18 Feb 2025, 16:55.

Change

Previous filing in this sequence was filed on 12 Nov 2024.
Current net transaction value: -$16,733.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CCCC transaction

Common Stock

Tax liability

Transaction value: $5,552
Shares: -1,735
Change %: -3.1%
Price: $3.20
Shares after: 54,832
Date: 13 Feb 2025
Ownership: Direct
Footnotes: F1

CCCC transaction

Common Stock

Award

Transaction value: $0
Shares: +56,500
Change %: +103%
Price: $0.000000
Shares after: 111,332
Date: 14 Feb 2025
Ownership: Direct
Footnotes: F2

CCCC transaction

Common Stock

Sale

Transaction value: $1,544
Shares: -490
Change %: -0.44%
Price: $3.15
Shares after: 110,842
Date: 14 Feb 2025
Ownership: Direct
Footnotes: F3

CCCC transaction

Common Stock

Tax liability

Transaction value: $7,530
Shares: -2,368
Change %: -2.1%
Price: $3.18
Shares after: 108,474
Date: 14 Feb 2025
Ownership: Direct
Footnotes: F1

CCCC transaction

Common Stock

Sale

Transaction value: $2,107
Shares: -669
Change %: -0.62%
Price: $3.15
Shares after: 107,805
Date: 18 Feb 2025
Ownership: Direct
Footnotes: F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CCCC transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +84,700
Change %
Price: $0.000000
Shares after: 84,700
Date: 14 Feb 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 84,700
Exercise price: $3.18
Footnotes: F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 4 footnotes

Footnote F1

Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs") and does not represent a sale by the Reporting Person.

Footnote F2

Represents RSUs. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs shall vest in four equal annual installments following the grant date, with the first installment vesting on February 14, 2026.

Footnote F3

This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 13, 2024.

Footnote F4

The shares underlying this option shall vest and become exercisable in forty-eight equal monthly installments following the grant date, with the first installment vesting on March 14, 2025.